Blog
RSS FeedPosted by Michael Wonder on 31 May 2024
Annual report highlights progress in science, medicines and health in 2023
30 May 2024 - EMA’s annual report 2023 published today details the Agency’s contributions to public and animal health in the ...
Posted by Michael Wonder on 16 Jan 2024
Human medicines: highlights of 2023
16 January 2024 - In 2023, EMA recommended 77 medicines for marketing authorisation. ...
Posted by Michael Wonder on 03 Mar 2022
PRIME enables earlier availability of life-changing medicines
3 March 2022 - EMA’s PRIority Medicines (PRIME) scheme has had a positive impact on the authorisation of new medicines that ...
Posted by Michael Wonder on 15 Feb 2022
Human medicines: highlights of 2021
15 February 2022 - In 2021, EMA recommended 92 medicines for marketing authorisation. Of these, 53 had a new active substance ...
Posted by Michael Wonder on 14 Feb 2022
EMA starts safety review of Janus kinase inhibitors for inflammatory disorders
11 February 2022 - EMA’s safety committee, PRAC, has started a review of the safety of Janus kinase (JAK) inhibitors ...
Posted by Michael Wonder on 05 Oct 2020
EU regulator starts safety review of coronavirus drug
3 October 2020 - The European Medicines Agency says it has started a safety review after some patients taking the ...
Posted by Michael Wonder on 30 Apr 2020
EMA starts rolling review of remdesivir for COVID-19
30 April 2020 - EMA’s human medicines committee (CHMP) has started a ‘rolling review’ of data on the use of ...
Posted by Michael Wonder on 09 Jan 2020
Human medicines: highlights of 2019
9 January 2020 - EMA has published a review of its key recommendations in 2019 on the authorisation and safety ...
Posted by Michael Wonder on 14 Apr 2019
Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing
12 April 2019 - EMA has started a review of the multiple sclerosis medicine Lemtrada (alemtuzumab) following new reports of ...
Posted by Michael Wonder on 26 Feb 2019
Procedural update on submission of Type I variations to EMA in March, April and May 2019
26 February 2019 - EMA is encouraging marketing authorisation holders intending to submit Brexit-related Type IA and Type IB variations ...
Posted by Michael Wonder on 24 Sep 2018
EMA to launch new corporate website on 27 September 2018
24 September 2018 - Fresh design and improved features to provide better user experience ...
Posted by Michael Wonder on 23 Jan 2018
Human medicines: highlights of 2017
23 January 2018 - 92 medicines recommended for approval, including 35 with a new active substance. ...
Posted by Michael Wonder on 17 Oct 2017
EMA’s procedural handling of safety review was complete and independent
17 October 2017 - European Ombudsman concludes her inquiry into the HPV vaccines referral. ...
Posted by Michael Wonder on 04 Oct 2017
EMA publishes comments on Member States’ hosting bids
3 October 2017 - Accessibility for delegates and experts and staff retention are key to ensure Agency’s ability to function ...
Posted by Michael Wonder on 07 May 2017
Conditional approval of medicines by the EMA
2 May 2017 - The process fails to improve the evidence after early licensing. ...